• cancer;
  • pediatrics;
  • qPCR;
  • MAGE;
  • NY-ESO-1


  1. Top of page
  2. Abstract
  3. Material and methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References

Cancer-germline genes (CGGs) code for immunogenic antigens that are present on various human tumors but not on normal tissues. The importance of CGGs in cancer immunotherapy has led to detailed studies of their expression in a range of human tumors. We measured the levels of expression of 12 CGGs in various pediatric solid tumors to identify targets for therapeutic cancer vaccines. Quantitative real-time PCR (qPCR) was used to measure the expression of 8 MAGE genes and of genes LAGE-2/NY-ESO-1 and GAGE-1, 2, 8 in 9 osteosarcomas, 10 neuroblastomas, 12 rhabdomyosarcomas and 18 Ewing's sarcomas. Nine tumors were also examined by immunohistochemistry with monoclonal antibodies specific for the MAGE-A1, MAGE-A4 and NY-ESO-1 proteins. All osteosarcoma and 80% of neuroblastoma samples expressed several CGGs at high levels. Six of 12 rhabdomyosarcomas and 11 of 18 Ewing's sarcomas expressed at least one CGG. Immunohistochemistry data correlated well with qPCR results and showed a homogeneous protein distribution pattern in most positive tumors. No correlation was found between the levels of CGG expression in the tumors and clinicopathological parameters of the patients. Pediatric solid tumors express several CGGs, which encode antigens that could be targeted in therapeutic vaccination trials. Several CGGs of the MAGE, GAGE and LAGE families are coexpressed in a large proportion of osteosarcoma and neuroblastoma samples. Some rhabdomyosarcomas express several of these genes at high levels. Ewing's sarcomas have an overall low CGG expression. © 2006 Wiley-Liss, Inc.

Human tumors bear antigens that can be specifically recognized by autologous T lymphocytes and antibodies.1, 2, 3 It has been shown in animal models and in clinical trials that vaccination with these tumor-specific antigens can lead to the eradication of tumors.4, 5 Over the last decade, promising new treatment modalities of induction of tumor-specific T cells have been proposed and applied.6, 7

Cancer-germline genes (CGGs) are expressed in male germline cells, not in other normal adult tissues, and in many tumors. Because male germline cells do not express HLA molecules on their surface, they do not express antigens that can be recognized by T cells. As a result, the antigens encoded by CGGs are strictly tumor-specific T cell or antibody targets. These antigens are shared by many tumors. CGGs include the MAGE,8, 9, 10 GAGE11, 12 and LAGE/NY-ESO-113, 14 families. The MAGE gene family comprises 24 genes ranged in 3 subfamilies, MAGE-A, -B and -C. A large number of antigenic peptides encoded by the MAGE, GAGE and LAGE/NY-ESO-1 genes have been found to be presented to CD4 and CD8 lymphocytes by HLA molecules expressed at the surface of tumor cells.15 Several clinical trials in which antigens encoded by CGGs were used as vaccines have shown induction of immunological responses and, in a small number of patients, clinical responses.16, 17, 18, 19, 20, 21, 22

Immunotherapy is an attractive therapeutic modality for pediatric cancer patients because it has a very mild toxicity, and the immune system of these patients is more potent and flexible compared with that of adults.23, 24 However, the development of appropriate vaccines has been hampered by the lack of knowledge regarding expression of tumor-specific antigens on pediatric tumors.

The aim of this study was to analyze the expression of CGGs in pediatric extracranial solid tumors. We report the results of a quantitative real-time PCR analysis of the expression of 12 CGGs in a panel of pediatric neuroblastomas, Ewing's sarcomas, rhabdomyosarcomas and osteosarcomas. For a subset of tumors, immunohistochemistry was used to analyze also the expression and distribution of proteins encoded by 3 CGGs.

Material and methods

  1. Top of page
  2. Abstract
  3. Material and methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References

Tumor samples

Fresh-frozen tumor samples were available at the Department of Pathology at the Radboud University Nijmegen Medical Centre. All samples were from pediatric patients (0 to 20-year-old) with a malignant solid extracranial tumor diagnosed at the Department of Pediatric Hemato-Oncology between 2000 and 2004. Sections of the frozen samples were stained with hematoxylin-eosin and reviewed by the pathologist to verify tumor histology and to evaluate the percentage of tumor cells. Samples were only considered for study if the contents of tumor cells was ≥80% and the yield of DNase-treated RNA was >1 μg.

RNA isolation and cDNA synthesis

Total RNA was isolated with TriZol reagent (Invitrogen, Carlsbad, CA) and samples were treated with deoxyribonuclease I (Invitrogen) according to the manufacturer's protocol. To generate cDNA, 1 μg DNase-treated RNA was reverse-transcribed with the SuperScript First-Strand Synthesis System for RT-PCR (Invitrogen) using oligo(dT) primer and 50 units SuperScript II, according to the manufacturer's protocol. After first-strand synthesis, samples were diluted to a final volume of 100 μl with water.

Conventional PCR

Duplex PCR amplification of β-actin and GAPDH transcripts was carried out in a 25-μl reaction volume containing 2.5 μl of cDNA, 1× PCR Buffer (10 mM Tris-HCl pH 8.3, 50 mM KCl, 1.5 mM MgCl2), 100 μM each dNTP, 0.4 μM each primer and 0.625 units Taq DNA polymerase (TaKaRa, Shiga, Japan). β-actin primers were as described.25GAPDH primers (originally available from Clontech, Palo Alto, CA; kindly provided by Dr. B. Lethé) were 5′-TgAAggTCggAgTCAACggATTTggT-3′ (sense) and 5′-CATgTgggCCATgAggTCCACCAC-3′ (antisense). Cycling was performed in a TRIO-Thermoblock thermocycler (Biometra, Göttingen, Germany) as follows: 94°C for 4 min, followed by 22 cycles of 1 min at 94°C, 1 min at 65°C, and 1 min at 72°C. Cycling was concluded with a final extension step at 72°C for 15 min. PCR products were fractionated in 1.3% agarose gel and visualized by ethidium bromide fluorescence (β-actin, 626 bp; GAPDH, 983 bp). PCR amplification of MAGE-A transcripts was carried out with the primer pair designed by Zammatteo et al.26 These primers derive from a consensus nucleotide sequence for the last exon of the 12 MAGE-A genes and give amplicons of (539 bp. PCR conditions were as described earlier, except that PCR was performed for 30 cycles.

Quantitative real-time PCR

Expression of CGGs and of the reference gene β-actin, was measured by quantitative PCR, based on TaqMan methodology, using the ABI PRISM 7700 Sequence Detection System (Applied Biosystems, Warrington, UK). PCR reactions were prepared with the qPCR Core Kit w/o dUTP reagents (Eurogentec, Seraing, Belgium). Each reaction (25 μl) contained 2.5 μl of cDNA, 1× PCR buffer containing the passive reference dye ROX, 5 mM MgCl2, 200 μM each dNTP, 200 nM each primer, 100 nM probe and 0.625 units DNA polymerase. Sequences of primers and probes, and thermal cycling conditions are available from the authors (Brasseur et al., manuscript in preparation). Probes with 6FAM and TAMRA labels were from Eurogentec. Probes with 6FAM and MGB-NFQ labels (for MAGE-A3 and MAGE-A6) were from Applied Biosystems. Quantification of the samples was achieved by extrapolation from a standard curve of 4 serial dilution points of cDNA of the relevant gene (from 105 to 102 copies per reaction for CGGs, and from 106 to 102 copies per reaction for β-actin). Samples and standard dilution points were assayed in duplicate or triplicate. Standard calibration curves for β-actin and all CGGs are shown in Figure 1. The assays were linear over 4 (CGGs) or 5 (β-actin) orders of magnitude and had similar PCR efficiencies (slope from −3.48 to −3.89). Differences in sensitivity between the assays for the various genes (y-intercept from 38.2 to 42.4) were due in part to differences in the actual cDNA copy number in the standard dilutions. cDNA copy numbers in the standards were verified by testing minimally 12 replicates of the 1-copy dilution in each qPCR run. If needed, copy numbers of the test samples were corrected by a factor calculated on the basis of the results for the 1-copy dilution. Normalization of samples was achieved by dividing the copy number of CGG by that of the reference gene, β-actin.

thumbnail image

Figure 1. Real-time qPCR: standard calibration curves for the 10 cancer-germline genes (CGGs) and the reference gene β-actin. Ct values (y-axis) were plotted against the logarithm of template cDNA copy numbers (x-axis). The assays were linear over 4 (CGGs) or 5 (β-actin) orders of magnitude.

Download figure to PowerPoint


Immunochemistry was performed on 4 μm tissue sections of formalin-fixed paraffin-embedded tissue blocks. Sections were boiled for 20 min in citrate buffer (10 mM, pH 6.0) for antigen retrieval. The following mouse IgG1 monoclonal antibodies (mAb) were used: E978 (anti-NY-ESO-1)27 (Zymed, San Francisco, CA), MA454 (anti-MAGE-A1)28 (Zymed) and 57B (anti-MAGE-A4)29, 30 (kindly provided by Dr. G.C. Spagnoli, University Hospital Basel, Switzerland). Testis tissue with intact spermatogenesis was used as positive control. Tissue sections were incubated with mAb diluted in PBA (2.5 μg/ml E978, 1 μg/ml MA454, 5 μg/ml 57B), or with IgG1 negative control antibody, at room temperature for 1 hr. Primary antibodies were then detected with a biotinylated horse-antimouse secondary reagent (Vector Laboratories, Burlingame, CA) followed by an avidin-biotin complex system (ABC Elite, Vector Laboratories). Diaminobenzidine tetrachloride served as a chromogen. Immunoreactivity was assessed by the pathologist, blindly with respect to the mAb used.


  1. Top of page
  2. Abstract
  3. Material and methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References

Study population

We analyzed the expression of cancer-germline genes (CGGs) in 49 freshly frozen tumors by reverse transcription and polymerase chain reaction (PCR) amplification. All samples were histologically proven malignant solid tumors of extracranial origin, resected from patients ≤20 years old at the time of surgery (Table I). The integrity of cDNA samples was verified by conventional, 22-cycles PCR amplification of 626 bp β-actin and 983 bp GAPDH products (data not shown). cDNA obtained from all 49 samples was then used as template in a conventional PCR amplification with consensus primers for the 12 genes of the MAGE-A family. Thirty-one samples scored positive, with 42–100% of positive samples depending on the type of tumor (Table I).

Table I. Study Group
Tumor typeNumber of patientsAverage age in years (range)% of MAGE-A-positive Tumors1
  • 1

    Gene expression was determined by conventional PCR with consensus primers for the 12 genes of the MAGE-A family.

  • 2

    5 Samples of alveolar and 7 of embryonic origin.

  • 3

    3 Samples were obtained after chemotherapy, represented by osteosarcoma bars 5, 6 and 8 in Fig. 2.

Neuroblastoma101 (0.2–3)80
Ewing's sarcoma1813 (2–20)50
Rhabdomyosarcoma1226 (0–20)42
Osteosarcoma9312 (9–16)100

CGG expression in pediatric tumors

The 31 MAGE-A-positive samples were tested by quantitative real-time PCR (qPCR), using TaqMan methodology, to measure the expression of MAGE-A1, A2, A3, A4, A6, A10 and A12. In addition, all 49 samples were tested by qPCR for expression of genes MAGE-C2, LAGE-2/NY-ESO-1 and GAGE. Quantification was obtained using standard curves, as explained in the Material and Methods section and Figure 1. Expression of GAGE was tested with a qPCR assay that detects GAGE-1, 2 and 8. CGG expression levels were calculated relative to β-actin expression (Fig. 2). For instance, the MAGE-A1/β-actin ratio for the first neuroblastoma sample was 1.1 × 10−2, indicating that 1.1 cDNA copies MAGE-A1 were present for every 100 cDNA copies of β-actin.

thumbnail image

Figure 2. Cancer-germline gene (CGG) expression in pediatric solid tumors measured by reverse transcription and quantitative real-time PCR. Each panel shows the results for one CGG in 49 different tumor samples (expression of GAGE was tested with a qPCR assay that detects GAGE-1, 2, and 8). Samples are arranged in the same order in all panels. The bars represent normalized CGG expression values (CGG/β-actin ratios). Small circles indicate samples in which the distribution of the MAGE-A1, MAGE-A4 and NY-ESO-1 proteins was assessed by immunohistochemistry (Figs. 3 and 4).

Download figure to PowerPoint


Eight of the 10 samples expressed at least 3 of the 7 MAGE-A genes that were tested. Expression of MAGE-C2, NY-ESO-1 or GAGE-1, 2, 8 was detected in 5 of the 8 MAGE-A-positive samples and in none of the negative samples. The pattern of expression of CGGs appeared to be highly clustered: all positive samples expressed at least 3 of the 10 genes tested (Table II). The levels of CGG expression in the neuroblastoma samples were usually high. For example, 3 samples expressed gene MAGE-A10 at a level that was only 100-fold lower than that of the expression of the β-actin gene (Fig. 2). Four out of the 10 samples expressed at least 1 CGG at a CGG/β-actin ratio >10−3.

Table II. Clustered Pattern of Cancer-Germline Gene Expression in Neuroblastoma Samples
  1. The signs +, ++, +++ and ++++ represent CGG/β-actin ratios ranging between 10−5 and 10−4, 10−4 and 10−3, 10−3 and 10−2, and ratios >10−2, respectively (Fig. 2). The sign – indicates that no CGG expression could be detected.

Ewing's sarcoma.

Eleven of the 18 Ewing's sarcoma samples expressed at least 1 CGG. Expression of MAGE-A1, MAGE-A2 and NY-ESO-1 could not be detected in any sample. Although a trend toward coexpression of multiple CGGs was observed, the number of coexpressed genes was less than in the other tumor types. The level of CGG expression in Ewing's sarcomas was always low (CGG/β-actin ratios <1 × 10−3).


Of the 12 samples, 6 expressed at least 1 CGG. The clustered pattern of expression of CGGs was most obvious in this tumor type: although 6 samples expressed no CGGs, 3 samples expressed at least 7 of the 10 genes. The level of expression in the positive samples was high. Three samples exhibited expression ratios >10−3 for 1 or more CGGs. These 3 samples also expressed NY-ESO-1 at levels >10−4.


The highest incidence of CGG expression was observed in these tumors: all 9 samples expressed at least 4 of the 7 MAGE-A genes that were tested. All samples expressed MAGE-A3 and A6. Seven samples expressed MAGE-C2, 8 expressed NY-ESO-1, and 9 expressed GAGE-1, 2, 8. Each sample expressed at least 6 of the 10 CGGs. MAGE-A4 was expressed less frequently (4 positive samples) than the other CGGs (6–9 positive samples). Osteosarcoma samples also expressed CGGs levels: in 8 of the 9 samples the CGG/β-actin ratio of at least 1 CGG was higher than 10−3. Expression ratios as high as 10−3 were observed for all CGGs except for MAGE-A4.

Cancer-germline protein distribution

Immunochemistry with monoclonal antibodies E978 (anti-NY-ESO-1), MA454 (anti-MAGE-A1) and 57B (anti-MAGE-A4) was performed on tissue sections from 9 tumors (identified with a circle in Fig. 2). Sections from normal testis tissue were used as positive controls. Representative results are shown in Figure 3. In testis, the 3 antibodies labeled spermatogonia and spermatocytes; spermatozoa were not stained. The staining with antibody E978 was less intense compared to antibodies MA454 and 57B, both in testis and tumor tissues. In tumors, the staining with MA454 or 57B was homogeneously distributed throughout the tissue, except for 1 neuroblastoma sample, which displayed a heterogeneous staining pattern with all 3 antibodies. This is illustrated in Figure 3, with high magnification inserts showing positive tumor cells positioned next to negative tumor cells in sample neuroblastoma 1. In the other positive tumors, the staining of the tumor cells with E978 had a homogeneous (1 tumor), heterogeneous (1 tumor) or focal (1 tumor) distribution. Immunohistochemistry and qPCR data of the 9 tested tumors correlated well. Staining of the tumor cells with each of the 3 antibodies was observed only in sections from tumors that tested positive for mRNA expression. No false-negative or false-positive immunohistochemistry result was observed in any of the 27 sections that were analyzed (chi-square, p < 0.001). No staining was observed with the IgG isotype negative control antibody.

thumbnail image

Figure 3. Immunohistochemistry with monoclonal antibodies MA454 (anti-MAGE-A1), 57B (anti-MAGE-A4), and E978 (anti-NY-ESO-1), and with IgG isotype negative control antibody on sections of normal testis (positive control) and pediatric tumor tissues (samples neuroblastoma 1, osteosarcoma 2, rhabdomyosarcoma 3, and Ewing's sarcoma 8 in Fig. 2). Original magnification 200×. The presence or absence of mRNA of MAGE-A1, MAGE-A4 or NY-ESO-1 in the sample (as tested by reverse transcription and qPCR; Fig. 2) is indicated by + or − for comparison. High magnification inserts (630×) demonstrate the heterogeneous staining patterns observed with all 3 antibodies in sample neuroblastoma sample 1.

Download figure to PowerPoint

The immunostaining of MAGE-positive cells in sample neuroblastoma 2, a metastatic lymph node from a neuroblastoma patient, clearly showed that the tumor cells invaded the parafollicular areas of the node. The B-cell areas, namely the follicle and the mantle zone, were not infiltrated by tumor cells (Fig. 4a). Hematoxylin-eosin staining confirmed that no tumor cells were present in the follicle and mantle zone (Fig. 4b).

thumbnail image

Figure 4. (a) Immunohistochemistry with the same antibodies as in Figure 3 on tissue sections of a metastatic neuroblastoma lymph-node (neuroblastoma sample 2 in Fig. 2). Original magnification 100×. + or − (Fig. 3). (b) Neuroblastoma sample 2, hematoxylin-eosin staining, original magnification 400×. Numbers in the figure represent 1. follicle; 2. mantle zone; 3. neuroblastoma tumor cells. (c) Correlation between cancer-germline gene (CGG) expression by the tumor and tumor stage in neuroblastoma. For each of the 10 tumors, CGG mRNA expression is reported as the sum of all CGG/β-actin ratios shown in Figure 2. Neuroblastoma IV-s is a special type of neuroblastoma characterized by metastatic disease with spontaneous regression and good survival.31 There is no significant correlation between level of CGG expression and neuroblastoma stage (r = 0.09; p = 0.79, calculated with the Spearman rank correlation).

Download figure to PowerPoint

CGG expression and tumor stage

Although the number of samples in each group of tumors was limited, the correlation between CGG expression and clinicopathological parameters was statistically analyzed. In none of the 4 groups a significant correlation could be observed between CGG mRNA expression by the tumors and parameters such as tumor stage (Fig. 4c shows the results for neuroblastomas), age of the patient and clinical outcome (data not shown).


  1. Top of page
  2. Abstract
  3. Material and methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References

The identification of tumor-specific antigens is an essential step in the development of therapeutic cancer vaccines. The importance of antigens encoded by CGGs as vaccine targets has led to detailed studies of their expression in various tumors.1, 32 Little information is available regarding expression of CGGs in pediatric tumors. Here we report CGG expression in pediatric solid tumors using quantitative real-time PCR. We observed that all osteosarcoma, most neuroblastoma and some rhabdomyosarcoma tumors expressed several CGGs at high levels. Ewing's sarcoma samples had an overall low CGG expression. CGG expression was not correlated with tumor stage or clinical parameters of the patients. CGG protein expression was confirmed by immunohistochemistry, with staining patterns that were frequently homogeneous.

In immunotherapeutic trials with defined tumor antigens, the level of expression of the target antigens may be of great importance for the success of the vaccine. Real-time quantitative PCR is a sensitive method for quantifying gene transcripts and is as such preferable to semiquantitative mRNA detection methods such as Northern blot and conventional PCR. Quantification of mRNA with real-time PCR needs appropriate standardization of the procedures for RNA extraction from tissues, cDNA synthesis and the real-time PCR itself.33 We had every tumor sample analyzed by the pathologist and selected only samples with more than 80% tumor cells. In addition, we calculated the mRNA expression levels of CGGs relative to those of the reference gene β-actin.

Our results indicate that CGG/β-actin ratios as high as 0.1 can be observed in some pediatric tumor samples. High CGG expression (CGG/β-actin ratio >1 × 10−3) was observed in most neuroblastoma samples and in 100% of the osteosarcomas. In the Ewing's sarcomas and rhabdomyosarcomas, we observed expression of at least 1 CGG in 61% and 50% of the samples, respectively. The CGG/β-actin ratio in Ewing's sarcoma was lower than 1 × 10−3 in all samples. Nonquantitative data on the expression of MAGE-A1, MAGE-A2, MAGE-A3 and NY-ESO-1 in pediatric neuroblastoma and rhabdomyosarcoma have been reported by others.34, 35, 36, 37, 38, 39 These data and ours correlate well.

We frequently observed coexpression of multiple CGGs in our tumor samples. This phenomenon has been described also for other tumors, and is most likely a consequence of a global demethylation of the genome in the tumor.40, 41 It is also possible that activation of a single CGG leads to the activation of other CGGs (reviewed by Simpson et al.32). The pattern of expression of CGGs that we observe in neuroblastoma is similar to that observed in melanomas,42, 43 which also develop from progenitor cells originating from the neural crest.

Numerous studies indicate that CGG expression is correlated with advanced pathologic stage and worse prognosis in various tumor types, including gastric carcinoma,44, 45 colorectal cancer,46 breast cancer,47, 48 ovarian neoplasm,49 bladder cancer,50 nonsmall-cell lung cancer51, 52 and multiple myeloma.53, 54 However, CGG expression is not correlated with disease progression in other malignancies such as neuroblastoma,34, 35, 36, 37 melanoma55 and esophageal cancer.56 We observed CGG expression in newly diagnosed tumors, in tumors collected after treatment with chemotherapy (osteosarcoma samples 5, 6 and 8 in Fig. 2) and in metastases. We could not detect a correlation between CGG expression in the tumor and clinicopathological parameters of the patients. Therefore, vaccination of these patients with CGG antigens is conceivable at all disease stages, including when a large tumor burden is present. And considering that pediatric tumors tend to coexpress multiple CGGs, one may target several antigens in the same patient, which should reduce the risk of resistance through antigen-loss tumor variants.57

Proteins MAGE-A1, MAGE-A4 and NY-ESO-1 were visualized with immunohistochemistry. MAGE-A1 and MAGE-A4 were homogeneously present in most tumors. NY-ESO-1, in contrast, had homogeneous, heterogeneous or focal distribution patterns. The 27 immunohistochemical stainings of the 9 tested tumors correlated well with the qPCR data. For a complete overview of CGG expression in a tumor, PCR data are essential because for most CGGs no specific antibodies are available. It is of note that in neuroblastoma sample 2, no MAGE-A3 mRNA expression was detected (Fig. 2) but staining of tumor cells by monoclonal antibody 57B was observed (Fig. 4a). This is in line with the observation that 57B, which was raised against a recombinant MAGE-A3 protein, does not detect MAGE-A3 but reliably detects MAGE-A4.30 As shown in Figures 4a and 4b, the distribution of neuroblastoma cells in the lymph node of neuroblastoma sample 2 had a unique pattern: the B-cell areas were free of tumor cells throughout the lymph node. We hypothesize that the microenvironment in the mantle zones of this lymph node prevents the tumor cells from entering the B-cell areas.

In conclusion, we report high levels of CGG expression in a large fraction of pediatric solid tumors. These data indicate that antigens encoded by these CGGs can be used to vaccinate children with these tumors.


  1. Top of page
  2. Abstract
  3. Material and methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References

The authors thank Riki Willems for assistance with the pathology database, Kim Vermeulen, Maaike Looman and Madeleine Swinarska for technical assistance.


  1. Top of page
  2. Abstract
  3. Material and methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References
  • 1
    Van Der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C, Schultz ES, Chapiro J, Van Den Eynde BJ, Brasseur F, Boon T. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 2002; 188: 5164.
  • 2
    Boon T, Cerottini JC, Van den Eynde B, Van Der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994; 12: 33765.
  • 3
    Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001; 411: 3804.
  • 4
    Velders MP, Markiewicz MA, Eiben GL, Kast WM. CD4+ T cell matters in tumor immunity. Int Rev Immunol 2003; 22: 11340.
  • 5
    Kershaw MH, Trapani JA, Smyth MJ. Cytotoxic lymphocytes: redirecting the cell-mediated immune response for the therapy of cancer. Ther Immunol 1995; 2: 17381.
  • 6
    Kalos M. Tumor antigen-specific T cells and cancer immunotherapy: current issues and future prospects. Vaccine 2003; 21: 7816.
  • 7
    Sinkovics JG, Horvath JC. Vaccination against human cancers (review). Int J Oncol 2000; 16: 8196.
  • 8
    van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 16437.
  • 9
    De Plaen E, Arden K, Traversari C, Gaforio JJ, Szikora JP, De Smet C, Brasseur F, van der Bruggen P, Lethe B, Lurquin C, Chomez P, De Backer O, et al. Structure, chromosomal localization and expression of 12 genes of the MAGE family. Immunogenetics 1994; 40: 3609.
  • 10
    Chomez P, De Backer O, Bertrand M, De Plaen E, Boon T, Lucas S. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res 2001; 61: 554451.
  • 11
    Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 1995; 182: 68998.
  • 12
    De Backer O, Arden KC, Boretti M, Vantomme V, De Smet C, Czekay S, Viars CS, De Plaen E, Brasseur F, Chomez P, Van den Eynde B, Boon T, et al. Characterization of the GAGE genes that are expressed in various human cancers and in normal testis. Cancer Res 1999; 59: 315765.
  • 13
    Lethe B, Lucas S, Michaux L, De Smet C, Godelaine D, Serrano A, De Plaen E, Boon T. LAGE-1, a new gene with tumor specificity. Int J Cancer 1998; 76: 9038.
  • 14
    Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M, Old LJ. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997; 94: 19148.
  • 15
    Van den Eynde B, Van der Bruggen P. T-cell defined tumor antigens. Curr Opin Immunol 1997; 9: 68493.
  • 16
    Chen Q, Jackson H, Parente P, Luke T, Rizkalla M, Tai TY, Zhu HC, Mifsud NA, Dimopoulos N, Masterman KA, Hopkins W, Goldie H, et al. Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proc Natl Acad Sci USA 2004; 101: 93638.
  • 17
    Davis ID, Chen W, Jackson H, Parente P, Shackleton M, Hopkins W, Chen Q, Dimopoulos N, Luke T, Murphy R, Scott AM, Maraskovsky E et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci USA 2004; 101: 10697702.
  • 18
    Jager E, Gnjatic S, Nagata Y, Stockert E, Jager D, Karbach J, Neumann A, Rieckenberg J, Chen YT, Ritter G, Hoffman E, Arand M, et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci USA 2000; 97: 12198203.
  • 19
    Marchand M, van Baren N, Weynants P, Brichard V, Dreno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y, Bourlond A, Vanwijck R, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999; 80: 21930.
  • 20
    van Baren N, Bonnet MC, Dreno B, Khammari A, Dorval T, Piperno-Neumann S, Lienard D, Speiser D, Marchand M, Brichard VG, Escudier B, Negrier S et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol 2005; 23: 900821.
  • 21
    Kruit WH, van Ojik HH, Brichard VG, Escudier B, Dorval T, Dreno B, Patel P, van Baren N, Avril MF, Piperno S, Khammari A, Stas M, et al. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer 2005; 117: 596604.
  • 22
    Marchand M, Punt CJ, Aamdal S, Escudier B, Kruit WH, Keilholz U, Hakansson L, van Baren N, Humblet Y, Mulders P, Avril MF, Eggermont AM, et al. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer 2003; 39: 707.
  • 23
    Mackall CL, Fleisher TA, Brown MR, Andrich MP, Chen CC, Feuerstein IM, Horowitz ME, Magrath IT, Shad AT, Steinberg SM, Wexler LH, Gress RE. Age, thymopoiesis and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995; 332: 1439.
  • 24
    Heitger A, Greinix H, Mannhalter C, Mayerl D, Kern H, Eder J, Fink FM, Niederwieser D, Panzer-Grumayer ER. Requirement of residual thymus to restore normal T-cell subsets after human allogeneic bone marrow transplantation. Transplantation 2000; 69: 236673.
  • 25
    Raff T, van der Giet M, Endemann D, Wiederholt T, Paul M. Design and testing of β-actin primers for RT-PCR that do not co-amplify processed pseudogenes. Biotechniques 1997; 23: 45660.
  • 26
    Zammatteo N, Lockman L, Brasseur F, De Plaen E, Lurquin C, Lobert PE, Hamels S, Boon T, Remacle J. DNA microarray to monitor the expression of MAGE-A genes. Clin Chem 2002; 48: 2534.
  • 27
    Jungbluth AA, Chen YT, Stockert E, Busam KJ, Kolb D, Iversen K, Coplan K, Williamson B, Altorki N, Old LJ. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 2001; 92: 85660.
  • 28
    Chen YT, Stockert E, Chen Y, Garin-Chesa P, Rettig WJ, van der Bruggen P, Boon T, Old LJ. Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies. Proc Natl Acad Sci USA 1994; 91: 10048.
  • 29
    Kocher T, Schultz-Thater E, Gudat F, Schaefer C, Casorati G, Juretic A, Willimann T, Harder F, Heberer M, Spagnoli GC. Identification and intracellular location of MAGE-3 gene product. Cancer Res 1995; 55: 22369.
  • 30
    Landry C, Brasseur F, Spagnoli GC, Marbaix E, Boon T, Coulie P, Godelaine D. Monoclonal antibody 57B stains tumor tissues that express gene MAGE-A4. Int J Cancer 2000; 86: 83541.
  • 31
    Nickerson HJ, Matthay KK, Seeger RC, Brodeur GM, Shimada H, Perez C, Atkinson JB, Selch M, Gerbing RB, Stram DO, Lukens J. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study. J Clin Oncol 2000; 18: 47786.
  • 32
    Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005; 5: 61525.
  • 33
    Bustin SA, Nolan T. Pitfalls of quantitative real-time reverse-transcription polymerase chain reaction. J Biomol Tech 2004; 15: 15566.
  • 34
    Soling A, Schurr P, Berthold F. Expression and clinical relevance of NY-ESO-1, MAGE-1 and MAGE-3 in neuroblastoma. Anticancer Res 1999; 19: 22059.
  • 35
    Ishida H, Matsumura T, Salgaller ML, Ohmizono Y, Kadono Y, Sawada T. MAGE-1 and MAGE-3 or -6 expression in neuroblastoma-related pediatric solid tumors. Int J Cancer 1996; 69: 37580.
  • 36
    Corrias MV, Scaruffi P, Occhino M, De Bernardi B, Tonini GP, Pistoia V. Expression of MAGE-1, MAGE-3 and MART-1 genes in neuroblastoma. Int J Cancer 1996; 69: 4037.
  • 37
    Cheung IY, Barber D, Cheung NK. Detection of microscopic neuroblastoma in marrow by histology, immunocytology and reverse transcription-PCR of multiple molecular markers. Clin Cancer Res 1998; 4: 28015.
  • 38
    Rodolfo M, Luksch R, Stockert E, Chen YT, Collini P, Ranzani T, Lombardo C, Dalerba P, Rivoltini L, Arienti F, Fossati-Bellani F, Old LJ, et al. Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen. Cancer Res 2003; 63: 694855.
  • 39
    Dalerba P, Frascella E, Macino B, Mandruzzato S, Zambon A, Rosolen A, Carli M, Ninfo V, Zanovello P. MAGE, BAGE and GAGE gene expression in human rhabdomyosarcomas. Int J Cancer 2001; 93: 8590.
  • 40
    Sahin U, Tureci O, Chen YT, Seitz G, Villena-Heinsen C, Old LJ, Pfreundschuh M. Expression of multiple cancer/testis (CT) antigens in breast cancer and melanoma: basis for polyvalent CT vaccine strategies. Int J Cancer 1998; 78: 3879.
  • 41
    De Smet C, Lurquin C, Lethe B, Martelange V, Boon T. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol 1999; 19: 732735.
  • 42
    Dalerba P, Ricci A, Russo V, Rigatti D, Nicotra MR, Mottolese M, Bordignon C, Natali PG, Traversari C. High homogeneity of MAGE, BAGE, GAGE, tyrosinase and Melan-A/MART-1 gene expression in clusters of multiple simultaneous metastases of human melanoma: implications for protocol design of therapeutic antigen-specific vaccination strategies. Int J Cancer 1998; 77: 2004.
  • 43
    Brasseur F, Rimoldi D, Lienard D, Lethe B, Carrel S, Arienti F, Suter L, Vanwijck R, Bourlond A, Humblet Y, Vacca A, Conese M, et al. Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 1995; 63: 37580.
  • 44
    Jung EJ, Kim MA, Lee HS, Yang HK, Lee YM, Lee BL, Kim WH. Expression of family A melanoma antigen in human gastric carcinoma. Anticancer Res 2005; 25: 210511.
  • 45
    Honda T, Tamura G, Waki T, Kawata S, Terashima M, Nishizuka S, Motoyama T. Demethylation of MAGE promoters during gastric cancer progression. Br J Cancer 2004; 90: 83843.
  • 46
    Li M, Yuan YH, Han Y, Liu YX, Yan L, Wang Y, Gu J. Expression profile of cancer-testis genes in 121 human colorectal cancer tissue and adjacent normal tissue. Clin Cancer Res 2005; 11: 180914.
  • 47
    Sugita Y, Wada H, Fujita S, Nakata T, Sato S, Noguchi Y, Jungbluth AA, Yamaguchi M, Chen YT, Stockert E, Gnjatic S, Williamson B, et al. NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors. Cancer Res 2004; 64: 2199204.
  • 48
    Otte M, Zafrakas M, Riethdorf L, Pichlmeier U, Loning T, Janicke F, Pantel K. MAGE-A gene expression pattern in primary breast cancer. Cancer Res 2001; 61: 66827.
  • 49
    Yakirevich E, Sabo E, Lavie O, Mazareb S, Spagnoli GC, Resnick MB. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms. Clin Cancer Res 2003; 9: 645360.
  • 50
    Kocher T, Zheng M, Bolli M, Simon R, Forster T, Schultz-Thater E, Remmel E, Noppen C, Schmid U, Ackermann D, Mihatsch MJ, Gasser T, et al. Prognostic relevance of MAGE-A4 tumor antigen expression in transitional cell carcinoma of the urinary bladder: a tissue microarray study. Int J Cancer 2002; 100: 7025.
  • 51
    Gure AO, Chua R, Williamson B, Gonen M, Ferrera CA, Gnjatic S, Ritter G, Simpson AJ, Chen YT, Old LJ, Altorki NK. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res 2005; 11: 805562.
  • 52
    Melloni G, Ferreri AJ, Russo V, Gattinoni L, Arrigoni G, Ceresoli GL, Zannini P, Traversari C. Prognostic significance of cancer-testis gene expression in resected non-small cell lung cancer patients. Oncol Rep 2004; 12: 14551.
  • 53
    van Rhee F, Szmania SM, Zhan F, Gupta SK, Pomtree M, Lin P, Batchu RB, Moreno A, Spagnoli G, Shaughnessy J, Tricot G. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood 2005; 105: 393944.
  • 54
    Dhodapkar MV, Osman K, Teruya-Feldstein J, Filippa D, Hedvat CV, Iversen K, Kolb D, Geller MD, Hassoun H, Kewalramani T, Comenzo RL, Coplan K, et al. Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7 and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer Immun 2003; 3: 9.
  • 55
    Busam KJ, Iversen K, Berwick M, Spagnoli GC, Old LJ, Jungbluth AA. Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters. Mod Pathol 2000; 13: 45965.
  • 56
    Akcakanat A, Kanda T, Tanabe T, Komukai S, Yajima K, Nakagawa S, Ohashi M, Hatakeyama K. Heterogeneous expression of GAGE, NY-ESO-1, MAGE-A and SSX proteins in esophageal cancer: implications for immunotherapy. Int J Cancer 2006; 118: 1238.
  • 57
    Khong HT, Wang QJ, Rosenberg SA. Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression. J Immunother 2004; 27: 18490.